Person:
DİNÇ, HARİKA ÖYKÜ

Profile Picture
Google ScholarScopusORCIDPublons
Status
Kurumdan Ayrılmıştır.
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
HARİKA ÖYKÜ
Last Name
DİNÇ
Name
Email Address
Birth Date

Filters

2015 - 201952020 - 20223
Reset filters

Settings

Author: Dinc, HARİKA ÖYKÜ × Author: Kocazeybek, Bekir ×

Search Results

Now showing 1 - 8 of 8
  • No Thumbnail Available
    PublicationMetadata only
    Waning of SARS-CoV-2 Vaccine-Induced Immune Response over 6 Months in Peritoneal Dialysis Patients and the Role of a Booster Dose in Maintaining Seropositivity
    (2022-05-01T00:00:00Z) Murt, Ahmet; Dinc, HARİKA ÖYKÜ; Altiparmak, Mehmet Riza; Yalin, Serkan F.; Yadigar, Serap; Parmaksiz, Ergun; Kocazeybek, Bekir; Pekpak, Meltem; Ataman, Muveddet Rezzan; DİNÇ, HARİKA ÖYKÜ
    Introduction: Although lower than general population, newly developed SARS-CoV-2 vaccines generate immune responses in end-stage kidney disease patients. However, the persistence of immune responses in the long term is not known yet. This study aimed to evaluate humoral immune responses in peritoneal dialysis (PD) patients over 6 months and to analyze the effects of the booster dose. Methods: Humoral immune responses of PD patients were measured after initial SARS-CoV-2 vaccinations and after 6 months following initial vaccinations. Immune responses were compared between patients who received and did not receive booster doses. PD patients were compared with 41 hemodialysis (HD) patients and 61 healthy controls. Humoral immune responses were measured by a commercial test that detects antibodies toward the receptor-binding domain of the spike protein of SARS-CoV-2. Results: Twenty PD patients were evaluated over 6 months. The initial seropositivity rate was 90.9% with inactivated vaccine and 100% with mRNA vaccine. Seropositivity decreased to 44.4% after 6 months, and a booster dose helped in maintaining the 100% of seropositivity (p = 0.005). Magnitude of humoral response at the 6th month was also higher in patients who received the third dose (1,132.8 +/- 769.6 AU/mL vs. 400.0 +/- 294.6 AU/mL; p = 0.015). Among patients who did not receive the third dose, those who got mRNA vaccine could maintain higher seropositivity than others who got inactivated vaccine (75% vs. 40% for PD, 81.8% vs. 50% for HD). Seropositivity and antibody levels were similar for PD and HD patients after 6 months (p = 0.24 and 0.56) but lower than healthy controls (p = 0.0013). Conclusion: SARS-CoV-2 vaccine-induced antibody levels and seropositivity of PD patients significantly fall after 6 months. A booster dose after around 3 months following initial immunization might help in maintaining seropositivity.
  • No Thumbnail Available
    PublicationMetadata only
    The prevalence of periodontal pathogenic bacteria in atherosclerotic cardiovascular disease
    (2020-01-01T00:00:00Z) Gode, Safa; Sarp, Tevhide Z.; Saribas, Suat; Ergin, Sevgi; Kasnak, Gökhan; Dinc, HARİKA ÖYKÜ; Caliskan, Reyhan; Akkus, Seher; Tokman, Hrisi B.; Kocak, Banu T.; Demirci, Mehmet; Gareayaghi, Nesrin; Kirmusaoglu, Sahra; Tokman, Halit; Kocazeybek, Bekir; DİNÇ, HARİKA ÖYKÜ
  • No Thumbnail Available
    PublicationMetadata only
    The role of adenovirus 36 as a risk factor in obesity: The first clinical study made in the fatty tissues of adults in Turkey
    (2015-03-01T00:00:00Z) Ergin, Sevgi; Altan, Eda; Pilanci, Ozgur; Sirekbasan, Serhat; Cortuk, Oguz; Cizmecigil, Utku; Ersin, Idris; Elbey, Huseyin; Dinc, HARİKA ÖYKÜ; Habip, Zafer; Turan, Nuri; Arinci, Atilla; Richt, Juergen A.; Goossens, Valere J.; Karakullukcu, Asiye; Kocak, Banu Tufan; Saribas, Suat; Koksal, Selcuk; Yilmaz, Huseyin; Kocazeybek, Bekir; DİNÇ, HARİKA ÖYKÜ
  • No Thumbnail Available
    PublicationMetadata only
    Evaluating the effectiveness of anti-tuberculosis treatment by detecting Mycobacterium tuberculosis 85B messenger RNA expression in sputum
    (2020-01-01T00:00:00Z) Atahan, Ersan; Saribas, Suat; Demirci, Mehmet; Babalık, Aylin; Akkus, Seher; Balıkcı, Ahmet; Satana, Dilek; Ziver, Tevhide; Dinc, HARİKA ÖYKÜ; Keskin, Melike; Ozbey, Dogukan; Kocak, Banu Tufan; Gareayaghi, Nesrin; Kirmusaoglu, Sahra; Tokman, Hrisi Bahar; Kocazeybek, Bekir; DİNÇ, HARİKA ÖYKÜ
  • No Thumbnail Available
    PublicationMetadata only
    Helicobacter pylori-miRNA interaction in gastric cancer tissues: First prospective study from Turkey
    (2019-01-01T00:00:00Z) Demiryas, Suleyman; Kocazeybek, Bekir; Demirci, Mehmet; Caliskan, Reyhan; Kepil, Nuray; Uysal, Hayriye Kirkoyun; Dinc, HARİKA ÖYKÜ; Saribas, Suat; Ergin, Sevgi; Erzin, Yusuf; Tasci, İhsan; Erdamar, Sibel; Demirdag, Cetin; Tokman, Hrisi Bahar; DİNÇ, HARİKA ÖYKÜ
  • No Thumbnail Available
    PublicationMetadata only
    Problems encountered in conventional HIV 1/2 algorithms: Lack of necessity for immunoblot assays to confirm repeated ELISA reactive results
    (2018-06-01T00:00:00Z) Yuksel, Pelin; Saribas, Suat; Kuskucu, Mert; Mutcali, Sibel Islak; Kosan, Erdogan; Habip, Zafer; Demirci, Mehmet; Kara, Eda Salihoglu; Birinci, Ilhan; Caliskan, Reyhan; Dinc, HARİKA ÖYKÜ; Midilli, Kenan; Ziver, Tevhide; Kocazeybek, Bekir; YÜKSEL MAYDA, PELİN; DİNÇ, HARİKA ÖYKÜ
    Background: The use of conventional (serologically based) HIV 1/2 diagnostic algorithms has become controversial in recent years.
  • Thumbnail Image
    PublicationOpen Access
    Diagnostic performance of the RT-qPCR method targeting 85B mRNA in the diagnosis of pulmonary Mycobacterium tuberculosis infection
    (2018-09-01T00:00:00Z) Demirci, Mehmet; Saribas, Suat; Ozer, Nigar; TOPRAK, Sezer; CAGLAR, Emel; ORTAKOYLU, Gonenc; Yuksel, PELİN; Ayaz, Gulsel; Tokman, Hrisi B.; Uysal, Omer; Dinc, HARİKA ÖYKÜ; ZİVER, Tevhide; Kocazeybek, Bekir; YÜKSEL MAYDA, PELİN; UYSAL, ÖMER; DİNÇ, HARİKA ÖYKÜ
    Background: Several nucleic acid amplification techniques (IS6110, 16S rRNA, and 85B mRNA) were developed for the rapid, direct detection of Mycobacterium tuberculosis. We aimed to assess the diagnostic performance of 85B mRNA-based RT-qPCR by comparing with the real-time PCR COBAS TagMan MTB Kit while using the BACTEC MGIT 960 method as the gold standard.
  • No Thumbnail Available
    PublicationMetadata only
    Evaluation of Adenovirus-36 (Ad-36) antibody seropositivity and adipokine levels in obese children
    (2017-07-01T00:00:00Z) Kocazeybek, Bekir; Dinc, HARİKA ÖYKÜ; Ergin, Sevgi; Saribas, Suat; Ozcabi, Bahar Taskm; Cizmecigil, Utku; Altan, Eda; Atalik, Keyser; Yuksel, Pelin; Taner, Zeynep; Karakullukcu, Asiye; Sirekbasan, Serhat; Turan, Nuri; Cagatay, Penbe; Imamova, Nergiz; Evliyaoglu, Olcay; Yilmaz, Huseyin; DİNÇ, HARİKA ÖYKÜ; YÜKSEL MAYDA, PELİN
    Adenovirus 36 (Ad-36) has recently been suggested as a possible contributor to the current obesity epidemic. The aim of this study was to investigate the prevalence of Ad-36 antibodies in obese children, as well as investigate the role of serum leptin and lipid levels in Ad-36-obesity. Seventy-one obese children and 62 non-obese children were included as the patient group (PG), including the healthy control group (HCG), respectively. Simultaneously, Ad-36 antibodies and adipokine levels were assessed with serum neutralization assays (SNA) and ELISA. Ad-36 antibody was detected in 9 patients (12.7%) and 1 patient (1.6%) in both the PG and HCG, respectively, while a significant difference was detected between groups (p < 0.05). Although serum LDL, total cholesterol, triglycerides and leptin levels were detected significantly higher, adiponectin level was detected paradoxically lower in the PG. However, a significant difference was not detected for lipids and leptin levels; adiponectin levels were found to be significantly lower in Ad-36 antibody-positive PG (p < 0.05).